share_log

Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target

Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target

Needham重申买入Cartesian Therapeutics,维持42美元的目标股价
Benzinga ·  05/08 11:40

Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $42 price target.

Needham分析师吉尔·布鲁姆重申Cartesian Therapeutics(纳斯达克股票代码:RNAC)的买入并维持42美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发